Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these ...
4d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
New research led by a Nashville physician is offering hope to children with sickle cell disease and another inherited blood ...
Zacks Investment Research on MSN
Can HCA's gene therapy milestone drive long-term growth?
HCA Healthcare, Inc. HCA is expanding its presence in advanced medicine after researchers from its Sarah Cannon Transplant ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results ...
Gene therapy has experienced an increasing number of successful human clinical trials, leading to numerous FDA-approved therapies based on recombinant viruses for rare disease, cancer, and other ...
A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...
Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results